Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies

Current Alzheimer Research

Volumn 2, Issue 1, 2005, Pages 3-18

  Ferrer, I ^a,d   Gomez Isla, T ^b   Puig, B ^a   Freixes, M ^a   Ribe E ^b   Dalfo E ^a   Avila, J ^c  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^d HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2; AMYLOID BETA PROTEIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIN DEPENDENT KINASE 5; GLYCOGEN SYNTHASE KINASE 3; MICROTUBULE AFFINITY REGULATING KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHOTRANSFERASE; PROTEIN KINASE (CALCIUM,CALMODULIN); STRESS ACTIVATED PROTEIN KINASE; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; APOPTOSIS; ARGYROPHILIC GRAIN DISEASE; CAENORHABDITIS ELEGANS; CELL CYCLE; CHROMOSOME 17; CORTICOBASAL DEGENERATION; DROSOPHILA; ENCEPHALITIS; ENZYME ACTIVATION; FRONTOTEMPORAL DEMENTIA; GLIA CELL; HUMAN; IMMUNIZATION; NEURITE; NEUROFIBRILLARY TANGLE; NEUROPIL; NONHUMAN; PARKINSONISM; PICK PRESENILE DEMENTIA; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN PHOSPHORYLATION; REVIEW; SENILE PLAQUE; TAUOPATHY; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; ANIMALS; ANNELIDA; BRAIN; DIPTERA; GLYCOGEN SYNTHASE KINASE 3; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MICE; MICE, TRANSGENIC; MICROTUBULE-ASSOCIATED PROTEINS; NEURONS; OXIDATIVE PHOSPHORYLATION; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; SUPEROXIDE DISMUTASE; TAU PROTEINS;

EID: 25844458239     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/1567205052772713     Document Type: Review

References (144)

1. Duyckaerts C, Dickson DW. Neuropathology of Alzheimer's disease. In: Neurodegeneration: the molecular pathology of dementia and movement disorders. (Edit D. Dickson), ISN Neuropath Press, Basel, p 47-68 (2003).
2. Herreman A, Serneels L, Annaert W, Collen D, Schoonjans L, De Strooper B. Total inactivation of γ-secretase activity in presenilin-deficient embryonic stem cells. Nat Cell Biol 2: 461-462 (2000).
3. Zhang Z, Nadeau P, Song W, Donoviel D, Yuan M, Bernstein A, Yankner BA. Presenilins are required for γ-secretase cleavage of β -APP and transmembrane cleavage of Notch-1. Nat Cell Biol 2: 463-465 (2000)
4. Bertram L, Tanzi R. Genetics of Alzheimer's disease. In: Neurodegeneration: the molecular pathology of dementia and movement disorders. (Edit D Dickson), ISN Neuropath Press, Basel, p 40-46 (2003).
5. Spillantini MG, Goedert M. Tau protein pathology in neurodegenerative diseases. Trends Neurosci 21: 428-433 (1998).
6. Buée L, Bussière T, Buée-Cherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Rev 33: 95-130 (2000).
7. Lee MVY, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annu Rev Neurosci 24: 1121-1159 (2001).
8. Togo T, Sahara N, Yen SH, Cookson N, Ishizawa T, Hutton M, De Silva R, Lees A, Dickson DW. Argyrophilic grain disease is a sporadic 4-repeat tauopathy. J Neuropathol Exp Neurol 61: 547-556 (2002).
9. Ingram EM, Spillantini MG. Tau gene mutations: dissecting the pathogenesis of FTDP-17. Trends Mol Med 8: 556-562 (2002).
10. Ghetti B, Hutton ML, Wszolek ZK. Frontotemporal dementia and parkinsonism linked to chromosome 17 associated with tau gene mutations (FTDP-17T). In: Neurodegeneration: The molecular pathology of dementia and movement disorders. (Edit D Dickson), ISN Neuropath Press, Basel, p 86-102 (2003).
11. Avila J. Tau aggregation into fibrillar polymers: taupathies. FEBS Lett 476: 89-92 (2000).
12. Avila J, Lim F, Moreno F, Belmonte C, Cuello AC. Tau function and dysfunction in neurons: its role in neurodegenerative disorders. Mol Neurobiol 25: 213-231 (2002).
13. Goedert M, Spillanini MG, Potier MC, Ulrich J, Crowther RA. Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain. EMBO J 8: 393-399 (1989)
14. Himmler A, Drechsel D, Kirschner MW, Martin DW. Tau consists of a set of proteins with repeat C-terminal microtubule-binding domains and variable N-terminal domains. Mol Cell Biol 9: 1381-1388 (1989).
15. Sun L, Liu SY, Zhou XW, Wang XC, Liu R, Wang Q, Wang JZ. Inhibition of protein phosphatase 2A- and protein phosphatase 1-induced tau hyperphosphorylation and impairment of spatial memory retention in rats. Neuroscience 118: 175-1182 (2003).
16. Ono T, Yamamoto H, Tashima K, Nakashima H, Okumura K, Yamada S, Hisanaga S, Kishimoto T, Miyakawa T, Miyamoto E. Dephosphorylation of abnormal sites of tau factor by proline phosphatases and its implication for Alzheimer's disease. Neurochem Int 26: 205-215 (1995).
17. Saito T, Ishiguro K, Uchida T, Miyamoto E, Kishimoto S, Hasanaga S. In situ dephosphorylation of tau by protein phosphatase 2A and 2B in fetal rat primary cultured neurons. FEBS Lett 376: 238-242 (1995).
18. Hanger DP, Hughes K, Woodgett JR, Brion JP, Anderton BH. Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localisation of the kinase. Neurosci Lett 147: 58-62 (1992).
19. Mandelkow EM, Drewes G, Biernat J, Gustke N, Van Lint J, Vandenheede JR and Mandelkow E. Glycogen synthase kinase-3 and the Alzheimer-like state of microtubule-associated protein tau. FEBS Lett 314: 315-321 (1992).
20. Goedert M, Hasegawa M, Jakes R, Lawler S, Cuenda A, Cohen P. Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases. FEBS Lett 409: 57-62 (1997).
21. Lovestone S, Reynolds CH. The phosphorylation of tau: a critical stage in neurodevelopment and neurodegenerative processes. Neuroscience 78: 309-324 (1997).
22. Reynolds CH, Nebreda AR, Gibb GM, Utton MA, Anderton BH. Reactivating kinase/p38 phosphorylates tau protein in vitro. J Neurochem 69: 191-198 (1997).
23. Reynolds CH, Utton MA, Gibb GM, Yates A, Anderton BH. Stress-activated protein kinase/c-Jun N-terminal kinase phosphorylates tau protein. J Neurochem 68: 1736-1744 (1997).
24. Goedert M, Spillantini MG, Davies SW. Filamentous nerve cell inclusions in neurodegenerative diseases. Curr Opin Neurobiol 8: 619-632 (1998).
25. Jenkins SM, Zinnerman M, Garner C, Johnson GV. Modulation of tau phosphorylation and intracellular localization by cellular stress. Biochem J 345 part 2: 263-270 (2000).
26. Reynolds CH, Betts JC, Blackstock WP, Nebreda AR, Anderton BH. Phosphorylation sites on tau identified by nanoelectrospray mass spectrometry: differences between the mitogen-activated protein kinases ERK2, c-Jun N-terminal kinase and p38, and glycogen synthase kinase-3β. J Neurochem 74: 1587-1595 (2000).
27. Buée-Scherrer V, Goedert M. Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells. FEBS Lett 515: 151-154 (2002).
28. Anderton BH, Betts J, Blackstock WP, Brion JP, Chapman S, Connell J, Dayanandan R, Gallo JM, Gibb G, Hanger DP, Hutton M, Kardalinou E, Leroy K, Lovestone S, Mack T, Reynolds CH, van Slegtenhorst M. Sites of phosphorylation in tau and factors affecting their regulation. Biochem Soc Symp 67: 73-80 (2001).
29. Wang J, Wang X, Liu R, Wang Q, Grundke-Iqbal I, Iqbal K. in vitro analysis of tau phosphorylation sites and its biological activity. Chin Med Sci J 17: 13-16 (2002).
30. Flaherty DB, Soria JP, Tomasiewicz HG, Wood JG. Phosphorylation of human tau protein by microtubule-associated kinases: GSK3beta and cdk5 are key participants. J Neurosci Res 62: 463-472 (2000).
31. Lee CW, Lau KF, Miller CC, Shaw PC. Glycogen synthase kinase-3_-mediated tau phosphorylation in cultured cells. NeuroReport 14: 257-260 (2003).
32. Takahashi M, Iseki E, Kosaka K. Cdk5 and munc-18/p67 colocalization in early stage neurofibrillary tangles-bearing neurons in Alzheimer type dementia brains. J Neurol Sci 172: 63-69 (2000).
33. Tandon A, Yu H, Wang L, Rogaeva E, Sato C, Chishti MA, Kawari T, Hasegawa H, Chen F, Davies P, Fraser PE, Westaway D, St George-Hyslop PH. Brain levels of CDK5 activator p25 are not increased in Alzheimer's or other neurodegenerative diseases with neurofibrillary tangles. J Neurochem 86: 572-581 (2003).
34. Stambolic A, Woodgett JR. Mitogen inactivation of glycogen synthase kinase 3_ in intact cells via serine9 phosphorylation. Biochem J 303: 701-704 (1994).
35. Cohen P, Frame S. The renaissance of GSK3. Nature Rev 2: 769-776 (2001).
36. Frame S, Cohen P, Biondi RM. A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation. Mol Cell 7: 1321-1327 (2001).
37. Singh TH, Zaidi T, Grundke-Iqbal I, Iqbal K. Modulation of GSK-3-catalyzed phosphorylation of microtubule-associated protein tau by non-proline-dependent protein kinases. FEBS Lett 358: 4-8 (1995).
38. Singh TJ, Haque N, Grundque Iqbal I, Iqbal K. Rapid Alzheimer-like phosphorylation of tau by the synergistic actions of non-proline-dependent protein kinases and GSK-3. FEBS Lett 358: 267-272 (1995).
39. Sengupta A, Wu Q, Grundke-Iqba I, Iqbal I, Iqbal K, Singh TJ. Potentiation of GSK-3-catalyzed Alzheimer-like phosphorylation of human tau by cdk5. Mol Cell Biochem 167: 99-105 (1997).
40. Zheng-Fischhöfer Q, Biernat J, Mandelkow EM, Illenberger S, Godermann R, Mandelkow E. Sequential phosphorylation of tau by glycogen synthase kinase-3β and protein kinase A at Thr212 and Ser214 generates the Alzheimer-specific epitope of antibody AT100 and requires a paired-helical filament conformation. Eur J Biochem 252: 542-552 (1998).
41. Shaw M, Cohen P. Role of protein kinase B and MAP kinase cascade in mediating EGF-dependent inhibition of glycogen synthase kinase 3 in Swiss 3T3 cells. FEBS Lett 461: 120-124 (1999).
42. Fang X, Yu SX, Lu Y, Bast RC, Woodgett JR, Mills GB. Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc Natl Acad Sci USA 97: 11960-11965 (2000).
43. Zhang F, Phiel CJ, Speces L, Gurvich N, Klin PS. Inhibitory phosphorylation of glycogen synthase kinase-3 (GSK-3) in response to lithium. J Biol Chem 278: 33067-33077 (2003).
44. Sakashita G, Shima H, Komatsu M, Urano T, Kikuchi A, Kikuchi K. Regulation of type 1 protein phosphatase/inhibitor-2 complex by glycogen synthase kinase-3β in intact cells. J Biochem 153: 165-171 (2003).
45. Xiao J, Perry G, Troncoso J and Monteiro MJ. Calcium-calmodulin-dependent kinase II is associated with paired helical filaments of Alzheimer's disease. J Neuropathol Exp Neurol 55: 954-963 (1996).
46. Pei JJ, Grundke-Iqbal I, Iqbal K, Bogdanovic N, Winblad B and Cowburn RF. Accumulation of cyclin-dependent kinase 5 (cdk-5) in neurons with early stages of Alzheimer's disease neurofibrillary degeneration. Brain Res 29: 267-277 (1998).
47. Pei JJ, Braak E, Braak H, Grundke-Iqbal I, Iqbal K, Winblad B, Cowburn RF. Distribution of glycogen synthase kinase 3 beta (GSK-3β) for Alzheimer disease neurofibrillary tangle. J Neuropathol Exp Neurol 58: 1010-1119 (1999).
48. Jicha GA, Weaver C, Lane E, Viana C, Kress Y, Rockwood J, Davies P. camp-dependent protein kinase phosphorylations on tau in Alzheimer's disease. J Neurosci 19: 7486-7494 (1999).
49. Perry G, Roder H, Nunomura A, Takeda A, Friedlich AL, Zhu X, Raina AL, Holbrook N, Siedlak SL, Harris PLR, Smith MA. Activation of extracellular receptor kinase (ERK) in Alzheimer's disease links oxidative stress to abnormal tau phosphorylation. NeuroReport 10: 2411-2415 (1999).
50. Hensley K, Floyd RA, Zheng NY, Nael R, Robinson KA, Nguyen X, Pye QN, Stewart CA, Geddes J, Markesbery WR, Patel E, Johnson GV, Bing G. p38 kinase is activated in the Alzheimer's disease brain. J Neurochem 72: 2053-2058 (1999).
51. Knowles RB, Chin J, Ruff CT, Hyman BT. Demonstration by fluorescence resonance energy transfer of a close association between activated MAP kinase and neurofibrillary tangles: implications for MAP kinase activation in Alzheimer's disease. J Neuropathol Exp Neurol 58: 1090-1098 (1999).
52. Schwab C, DeMaggio AJ, Ghoshal N, Binder LI, Kuret J, McGeer PL. Casein kinase 1 delta is associated with pathological accumulation of tau in several neurodegenerative diseases. Neurobiol Aging 21: 503-510 (2000).
53. Zhu X, Rottkamp CA, Boux H, Takeda A, Perry G and Smith MA. Activation of p38 kinase links tau phosphorylation, oxidative stress, and cell cycle-related events in Alzheimer disease. J Neuropathol Exp Neurol 59: 880-888 (2000).
54. Atzori C, Ghetti B, Piva R, Srinivasan AN, Zolo P, Delisle MB, Mirra SS, Migheli A. Activation of the JNK/p38 pathway occurs in diseases characterized by tau protein pathology and is related to tau phosphorylation but not to apoptosis. J Neuropathol Exp Neurol 60: 1190-1197 (2001).
55. Ferrer I, Blanco R, Carmona M, Ribera R, Goutan E, Puig B, Rey MJ, Cardozo A, Viñals F and Ribalta T. Phosphorylated MAP kinase (ERK1, ERK2) expression is associated with early tau deposition in neurones and glial cells, but not with increased nuclear DNA vulnerability and cell death, in Alzheimer's disease. Pick's disease, progressive supranuclear palsy and corticobasal degeneration. Brain Pathol 11: 144-158 (2001).
56. Ferrer I, Blanco R, Carmona M, Puig B. Phosphorylated mitogen-activated protein kinase (MAPK/ERK-P), protein kinase of 38 kDa (p38-P), stress-activated protein kinase (SAPK/JNK-P), and calcium/calmodulin-dependent kinase II (CaM kinase II) are differentially expressed in tau deposits in neurons and glial cells in tauopathies. J Neural Transm 108: 1397-1415 (2001).
57. Pei JJ, Braak E, Braak H, Grundque-Iqbal K, Winblad W, Cowburn RF. Localization of active forms of c-Jun kinase (JNK) and p38 kinase in Alzheimer's disease brains at different stages of neurofibrillary degeneration. J Alzheimer's Dis 3: 41-48 (2001).
58. Zhu X, Raina AK, Rottkamp CA, Aliev G, Perry G, Boux H, Smith MA. Activation and redistribution of c-Jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease. J Neurochem 76: 435-441 (2001).
59. Ferrer I, Barrachina M, Puig B. Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration. Acta Neuropathol 104: 583-591 (2002).
60. Zhu X, Sun Z, Lee HG, Siedlak SL, Perry G. Smith MA. Distribution, levels, and activation of MEK1 in Alzheimer's disease. J Neurochem 86: 136-142 (2003)
61. Phiel CJ, Wilson CA, Lee VM, Klein PS. GSK-3α regulates production of Alzheimer's disease amyloid β peptides. Nature 423: 435-439 (2003).
62. Pei JJ, Braak E, Braak H, Grundke-Iqbal I, Iqbal K, Winblad B, Cowburn RF. Distribution of active glycogen synthase kinase 3α (GSK-3β) in brains staged for Alzheimer disease neurofibrillary changes. J Neuropathol Exp Neurol 58: 1010-1019 (1999).
63. Leroy K, Boutajangout A, Authelet M, Woodgett JR, Anderton BH, Brion JP. The active form of glycogen synthase kinase-3β is associated with granulovacuolar degeneration in neurons in Alzheimer's disease. Acta Neuropathol 103: 91-99 (2002).
64. Pei JJ, Khatoon S, An W-L, Nordlinder M, Tanaka T, Braak H, Tsujio I, Takeda M, Alafuzoff I, Winblad B, Cowburn RF, Grundke-Iqbal I, Iqbal K. Role of protein kinase B in Alzheimer's neurofibrillary pathology. Acta Neuropathol 105: 381-392 (2003).
65. Cross D, Culbert A, Chalmers KA, Facci L, Skaper SD, Reith AD. Selective small molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurons from death. J Neurochem 77: 94-102 (2001).
66. Xie L, Helmerhorst E, Taddei K, Plewright B, van Bronswijk W, Martins R. Alzheimer's amyloid peptides compete for insulin binding to the insulin receptor. J Neurosci 22: 221RC (2002).
67. Zhu X, Ogawa O, Wang Y, Perry G, Smith MA. JKK1, an upstream activator of JNK/SAPK, is activated in Alzheimer's disease. J Neurochem 85: 87-93 (2003).
68. Zhu X, Rottkamp CA, Hartzler A, Sun Z, Takeda A, Boux H, Shimohama S, Perry G, Smith MA. Activation of MKK6, an upstream activator of p38, in Alzheimer's disease. J Neurochem 79: 311-318 (2001).
69. Hartzler AW, Zhu X, Siedlak SL, Castellani RJ, Avila J, Perry G. Smith MA. The p38 pathway is activated in Pick disease and progressive supranuclear palsy: a mechanistic link between mitogenic pathways, oxidative stress and tau. Neurobiol Aging 23: 855-859 (2002).
70. Ferrer I, Barrachina M, Tolnay M, Rey MJ, Vidal N, Carmona M, Blanco R, Puig B. Phosphorylated protein kinases associated with neuronal and glial tau deposits in argyrophilic grain disease. Brain Pathol 13: 62-78 (2003).
71. Ferrer I, Pastor P, Rey MJ, Muñoz E, Puig B, Pastor E, Oliva R, Tolosa E. Tau phosphorylation and kinase activation in familial tauopathy linked to delN296 mutation. Neuropathol Appl Neurobiol 29: 23-34 (2003).
72. Ferrer I, Hernandez I, Puig B, Rey MJ, Ezquerra M, Tolosa E, Boada M. Ubiquitin-negative mini-Pick-like bodies in the dentate gyrus in P301L tauopathy. J Alzheimer Dis 5: 445-454 (2003).
73. Puig B, Viñals F, Ferrer I. Active stress kinase p38 enhances and perpetuates abnormal tau phosphorylation and deposition in Pick's disease. Acta Neuropathol 107: 185-189 (2004).
74. Higgins LS, Holtzman DM, Rabin J, Mobley WC, Cordell B. Transgenic mouse brain histopathology resembles early Alzheimer's disease. Ann Neurol 35: 598-607 (1994).
75. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T and Gillespie F. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 349: 704-706 (1995).
76. Hsiao K, Chapman P, Nilsen S, Exkman C, Harigaya Y, Younkin S, Yang F, Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274: 99-102 (1996).
77. Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, Ledermann B, Burki K, Frey P, Paganetti PA, Waridel C, Calhoun ME, Jucker M, Probst A, Staufenbiel M, Sommer B. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA 94: 13287-13292 (1997).
78. Borchelt DR, Ratovitsi T, van Lare J, Lee MK, Gozales V, Jenkins NA, Copeland NG, Price DL, Sisodia SS. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 19: 939-945 (1997).
79. Borchelt DR, Wong PC, Sisodia SS, Price DL. Transgenic mouse models of Alzheimer's disease and amyotrophic lateral sclerosis. Brain Pathol 8: 735-757 (1998).
80. Guenette SY, Tanzi RE. Progress toward valid transgenic mouse models for Alzheimer's disease. Neurobiol Aging 20: 201-211 (1999).
81. van Leuven F. Single and multiple transgenic mice as models for Alzheimer's disease. Progr Neurobiol 61: 305-312 (2000).
82. McGowan E, Pickord F, Dickson DW. Alzheimer animal models: models of Aβ deposition in transgenic mice. In: Neurogeneration: the molecular pathology of dementia and movement disorders, (Edit D Dickson), ISN Neuropath Press, Basel, p 74-79 (2003).
83. Irizarry MC, Soriano F, McNamara M, Page KJ, Schenk D, Games D, Hyman BT. Aβ deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J Neurosci 17: 7053-7059 (1997).
84. Irizarry MC, McNamara M, Fedorchak K, Hsiao K, Hyman BT. APPSw transgenic mice develop age-related Aβ deposits and neuropil abnormalities, but no neuronal loss in CA1. J Neuropathol Exp Neurol 56: 965-973 (1997).
85. Holcomb L, Gordon MN, McGowan E. Yu X, Benkovic S, Janyzen P, Wright K, Saad I, Mueller R, Morgan D, Sanders S, Zehr C, O'Campo K, Hardy J, Prada CM, Eckman C, Younkin S, Hsiao K, Duff K. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenelin 1 transgenes. Nat Med 4: 97-100 (1998).
86. Borchelt DR, Lee MK, Gozales V, Slunt HH, Ratovitsky T, Jenkins NA, Copeland NG. Price DL, Sisodia SS. Accumulation of proteolytic fragments of mutant presenilin 1 and accelerated amyloid deposition are co-regulated in transgenic mice. Neurobiol Aging 23: 171-177 (2002).
87. Masliah E, Sisk A, Mallory M, Games D. Neurofibrillary pathology in transgenic mice overexpressing V717F _-amyloid precursor protein. J Neuropathol Exp Neurol 60: 357-368 (2001).
88. Tomidokoro Y, Harigaya Y, Matsubara E, Ikeda M, Kawarabayashi T, Shirao T, Ishiguro K, Okamoto K, Younkin SG, Shoji M. Brain Aβ amyloidosis in APP(Sw) mice induces accumulation of presenilin-1 and tau. J Pathol 194: 500-506 (2001).
89. Otth C, Concha II, Arendt T, Stieler J, Schliebs R, González- Billault C, Maccioni RB. AβPP induces cdk5-dependent tau hyperphosphorylation in transgenic mice Tg2576. J Alzheimer Dis 4: 417-430 (2002).
90. Cedazo-Minguez A, Popescu BO, Blanco-Millan JM, Akterin S, Pei JJ, Winblad B, Cowburn RF. Apolipoprotein E and β-amyloid (1-42) regulation of glycogen synthase kinase-3β. J Neurochem 87: 1152-164 (2003).
91. Savage MJ, Lin YG, Ciallella JR, Flood DG, Scott RW. Activation of c-Jun N-terminal kinase and p38 in an Alzheimer's disease model is associated with amyloid deposition. J Neurosci 22: 3376-3385 (2002).
92. Puig B, Gómez-Isla T, Ribe E, Cuadrado M, Ferrer I. Expression of stress-activated kinases c-Jun N-terminal kinase (SAPK/JNK-P) and p38 kinase (p38-P) links oxidative stress and tau hyperphosphorylation in neurites surrounding Aβ plaques in APP Tg2576 mice. Neuropathol Appl Neurobiol (in press).
93. Hutton M, Lewis J, Dickson D, Yen SH, McGowan E. Analysis of tauopathies with transgenic mice. Trends Mol Med 7: 467-470 (2001).
94. Götz J. Tau and transgenic animal models. Brain Res Rev 35: 266-286 (2001).
95. Lewis J, Dickson DV. Transgenic animal models of tauopathies. In: Neurodegeneration: The molecular pathology of dementia and movement disorders. (Edit D Dickson). ISN Neuropath Press, Basel, p 150-154 (2003).
96. Boutajangout A, Leroy K, Touchet N, Authelet M, Blanchard V, Tremp G, Pradier L, Brion JP. Increased tau phosphorylation but absence of formation of neurofibrillary tangles in mice double transgenic for human tau and Alzheimer mutant (M146L) presenilin-1. Neurosci Lett 318: 29-33 (2002).
97. Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, van Slegtenhorst M, Gwinn-Hardy K, Paul Murphy M, Baker M, Yu X, Hardy J, Corral A, Lin WL, Yen SH, Dickson DW, Davies P, Hutton M. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau proteins. Nat Genet 25: 402-405 (2000).
98. Götz J, Chen F, Barmettler R, Nitsch RM. Tau filament formation in transgenic mice expressing P301L tau. J Biol Chem 276: 529-534 (2001).
99. Allen B, Ingram E, Takao M, Smith MJ, Jakes R, Virdee K, Yoshida H, Holzer M, Craxton M, Emson PC, Atzori C, Migheli A, Crowther RA, Ghetti B, Spillantini MG, Goedert M. Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau. J Neurosci 22: 9340-9351 (2002).
100. Tanemura K, Akagi T, Muruyama M, Kikuchi N, Murayama O, Hashikama Y, Yoshiike Y, Park JM, Matsuda K, Nakao S, Sun X, Sato S, Yamaguchi H, Takashima A. Formation of filamentous tau aggregates in transgenic mice expressing V337M human tau. Neurobiol Dis 8: 1036-1045 (2001).
101. Götz J, Chen F, Barmettler R, Nitsch RM. Tau filament formation in transgenic mice expressing P301L tau. J Biol Chem 276: 529-534 (2001).
102. Tatebayashi Y, Miyasaka T, Chui DH, Akagi T, Mishima KI, Iwasaki K, Fujiwara M, Tanemura K, Murayama M, Ishiguro K, Planel E, Sato S, Hashikawa T, Takashima A. Tau filament formation and associative memory deficit in aged mice expressing mutant (R406W) human tau. Proc Natl Acad Sci USA 99: 13896-13901 (2002).
103. Lim F, Hernandez F, Lucas JJ, Gómez-Ramos P, Morán MA, Avila J. FTDP-17 mutations in tau transgenic mice provoke lysosomal abnormalities and tau filaments in the forebrain. Mol Cell Neurosci 18: 702-714 (2001).
104. Ishizawa T, Sahara N, Ishiguro K, Kersh J, McGowan E, Lewis J, Hutton M, Dickson DW, Yen SH. Co-localization of glycogen synthase kinase-3 with neurofibrillary tangles and granulovacuolar degeneration in transgenic mice. Am J Pathol 163: 1057-1067 (2003).
105. Perez M, Hernandez F, Lim F, Diaz-Nido J, Avila J. Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model. J Alzheimer Dis 5: 301-308 (2003).
106. Ahlijanian MK, Barrezueta NX, Willimas RD, Jakowski A, Kopwsz KP, McCarthy S, Coskran T, Carlo A, Seymour PA, Burkhardt JE, Nelson RB, McNeish JD. Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5. Proc Natl Acad Sci USA 97: 2910-2915 (2000).
107. Noble W, Olm V, Takata K, Casey E, Mary O, Meyerson J, Gaynor J, Lafrancois J, Wang L, Kondo T, Davies P, Burns M, Veeranna, Dickson D, Matsuoka Y, Ahlijanian M, Lau LF, Duff K. cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron 38: 555-565 (2003).
108. Takashima A, Murayama M, Yasutake K, Takahashi H, Yokoyama M, Ishiguro K. Involvement of cyclin dependent kinase5 activator p25 on tau phosphorylation in mouse brain. Neurosci Lett 306: 37-40 (2001).
109. Spittaels K, Van den Haute C, Van Dorpe J, Geerts H, Mercken M, Sciot R, Van Lammel A, Loos R, van Leuven F. Glycogen synthase kinase-3β phosphorylates protein τ and rescues the axonopathy in the central nervous system of human four-repeat τ transgenic mice. J Biol Chem 275: 413440-413449 (2000).
110. Lucas JJ, Hernandez F, Gómez-Ramos P, Morán MA, Hen R, Avila J. Decreased nuclear β-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3β conditional transgenic mice. EMBO J 20: 27-39 (2001).
111. Hernandez F, Borrell J, Guaza C, Avila J, Lucas JJ. Spatial learning deficit in transgenic mice that conditionally express GDK-3β in the brain but do not form tau filaments. J Neurochem 83: 1529-15333 (2002).
112. Kins S, Crameri A, Evans DRH, Hemmings BA, Nitsch R, Götz J. Reduced PP2A activity induces tau hyperphosphorylation and altered compartmentalization of tau in transgenic mice. J Biol Chem 276: 38193-38200 (2001).
113. Kins S, Kurosinski P, Nitsch RM, Götz J. Activation of the ERK and JNK signaling pathways caused by neuron-specific inhibition of PP2A in transgenic mice. Am J Pathol 163: 883-843 (2003).
114. Liou YC, Sun A, Ryo A, Zhou XZ, Huang ZH, Uchida T, Bronson R, Li GX, Hunter T, Lu KP. Role of the prolyl isomerase Pin1 in protecting against age-dependent neurodegeneration. Nature 424: 556 (2003).
115. Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, Yen SH, Sahara N, Skipper L, Yager D, Eckman C, Hardy J, Hutton M, McGowan E. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293: 1487-1491 (2001).
116. Jackson GR, Wiedau-Pazos M, Sang TK, Wagle N, Brown CA, Massachi S, Geshwind DH. Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila. Neuron 34: 509-519 (2002).
117. Mudher A, Shepherd D, Newman TA, Mildren P, Jukes JP, Squire A, Mears A, Berg S, MacKay D, Asuni A, Bhat R, Lovestone S. GSK-3_ inhibition reverses axonal transport defects and behavioral phenotypes in Drosophila. Mol Psychiatr (in press)
118. Shulman JM, Feany MB. Genetic modifiers of tauopathy in Drosophila. Genetics 165: 1233-1242 (2003).
119. Nishimura I, Yang Y, Lu B. PAR-1 kinase plays an initiator role in a temporally ordered phosphorylation process that confers tau toxicity in Drosophila. Cell 116: 671-682 (2004).
120. Kraemer BC, Zhang B, Leverenz JB, Thomas JH, Trojanowski JQ, Schellenberg GD. Neurodegeneration and defective neurotransmission in a Caenorhabditis elegans model of tauopathy. Proc Natl Acad Sci USA 100: 9653-9655 (2003).
121. Nicoll JAR, Wilkinson D, Holmes C, Steart O, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nat Med 9: 4448-452 (2003).
122. Ferrer I, Boada-Rovira M, Sanchez-Guerra ML, Rey MJ, Costa-Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid-β immunization in Alzheimer's disease. Brain Pathol 14: 11-20 (2004).
123. Ferrer I, Blanco R, Carmona M, Puig B. Phosphorylated c-Myc expression in Alzheimer disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration. Neuropathol Appl Neurobiol 27: 343-351 (2001).
124. McShea A, Harris K, Webster KR, Wahl AF, Smith MA. Abnormal expression of the cell cycle regulators P16 and CDK4 in Alzheimer's disease. Am J Pathol 150: 1933-1939 (1997).
125. Nagy Z, Esiri MM, Cato AM, Smith AD. Cell cycle markers in the hippocampus in Alzheimer's disease. Acta Neuropathol 94: 6-15 (1997).
126. Arendt T, Holzer M, Gartner U, Bruckner MK. Aberrances in signal transduction and cell cycle related events in Alzheimer's disease. J Neural Transm 54: 147-158 (1998).
127. Busser J, Geldmacher DS, Kerrup K. Ectopic cell cycle proteins predict the sites of neuronal cell death in Alzheimer's disease brain. J Neurosci 15: 2801-2807 (1998).
128. Copani A, Uberti D, Sortino MA, Bruno V, Nicoletti F, Memorandum M. Activation of cell-cycle-associated proteins in neuronal death: a mandatory or dispensable path? Trends Neurosci 24: 25-31 (2001).
129. Obaya AJ, Mateyak MK, Sedivy JM. Mysterious liaisons: the relationship between c-Myc and the cell cycle. Oncogene 18: 2934-2941 (1999).
130. Gregory MA, Qi Y, Hann SR. Phosphorylation by glycogen synthase kinase-3 controls c-Myc proteolysis and subnuclear localization. J Biol Chem 16: on line Oct (2003).
131. Daniels WM, Hendricks J, Salie R, Taljaard JJ. The role of MAP-kinase superfamily in β-amyloid toxicity. Metab Brain Dis 16: 175-185 (2001).
132. Morishima Y, Gotoh Y, Zieg J, Barrett T, takano H, Flavell R, Davis RJ, Shirasaki Y, Greenberg ME. β-amyloid induces neuronal apopotosis via a mechanism that involves the c-Jun N-terminal kinase pathway and the induction of Fas ligand. J Neurosci 21: 7551-7560 (2001).
133. Bozyczko-Coyne D, O'Kane TM, Wu ZL, Dobrzanski P, Murphy S, Vaught JL, Scott RW. CEP-1347/KT-7515, an inhibitor of SAPK/JNK pathway activity, promotes survival and blocks multiple events associated with A_-induced cortical neuron apoptosis. J Neurochem 77: 849-863 (2001).
134. Troy CM, Rabacchi SA, Xu Z, Maroney AC, Connors TJ, Shelanski ML, Greene LA. Beta-amyloid-induced neuronal apoptosis requires c-Jun N-terminal kinase activation. J Neurocem 77: 157-164 (2001).
135. Wei W, Wang X, Kusiak JW. Signaling events in amyloid _-peptide-induced neuronal death and insulin-like growth factor I protection. J Biol Chem 277: 17649-17656 (2002).
136. Wei W, Norton DD, Wang X, Kusiak JW. Aβ 17-42 in Alzheimer's disease activates JNK and caspase-8 leading to neuronal apoptosis. Brain 125: 2036-2043 (2002).
137. Jang JH, Surth YJ. β-amyloid induces oxidative DNA damage and cell death through activation of c-Jun N terminal kinase. Ann NY Acad Sci 973: 228-236 (2002).
138. 2 and 4-hydroxynonenal mediate β-amyloid-induced neuronal apoptosis by activating JNKs and p38 MAPKs. Exp Neurol 180: 144-155 (2003).
139. Fogarty MP, Downer EJ, Campbell V. A role for c-Jun N-terminal kinase 1 (JNK-1), but not JNK2, in the beta-amyloid-mediated stabilization of protein p53 and induction of the apoptotic cascade in cultured cortical neurons. Biochem J 371: 789-798 (2003).
140. Selznick LA, Holtnman DM, Han BH, Gökden M, Srinavasan AN, Jonson EM, Roth KA. In situ immunodetection of neuronal caspase-3 activation in Alzheimer's disease. J Neuropathol Exp Neurol 58: 1020-1026 (1999).
141. Zhu X, Raina AK, Lee HG, Chao M, Nunomura A, Tabaton M, Petersen RB, Perry G, Smith MA. Oxidative stress and neuronal adaptation in Alzheimer disease: The role of SAPK pathways. Antioxid Redox Signal 5: 571-576 (2003).
142. Morsch W, Simon W, Coleman PD. Neurons may live for decades with neurofibrillary tangles. J Neuropathol Exp Neurol 58: 188-197 (1999).
143. Hamdane M, Delobel P, Sambo AV, Smet C, Begard S, Violleau A, Landrieu I, Delacourte A, Lippens G, Flament S, Buée L. Neurofibrillary degeneration to the Alzheimer-type: an alternative pathway to neuronal apoptosis? J Biochem Pharmacol 15: 1619-1625 (2003).
144. Ferrer I. Differential expression of phosphorylated translation initiation factor 2 alpha in Alzheimer's disease and Creutzfeldt-Jakob disease. Neuropathol Appl Neurobiol 28: 441-451 (2002).